LMAT stock icon

LeMaitre Vascular

92.93 USD
+2.54
2.81%
At close Oct 9, 4:00 PM EDT
After hours
92.93
+0.00
0.00%
1 day
2.81%
5 days
2.73%
1 month
7.41%
3 months
11.13%
6 months
38.78%
Year to date
63.87%
1 year
63.06%
5 years
196.71%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Employees: 630

0
Funds holding %
of 6,740 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more call options, than puts

Call options by funds: $296K | Put options by funds: $74K

150% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 5 (+3) [Q2]

73% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 26

24% more capital invested

Capital invested by funds: $1.36B [Q1] → $1.69B (+$327M) [Q2]

8% more funds holding

Funds holding: 242 [Q1] → 261 (+19) [Q2]

0.55% less ownership

Funds ownership: 92.05% [Q1] → 91.5% (-0.55%) [Q2]

7% less repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 98

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
12%
downside
Avg. target
$91
2%
downside
High target
$100
8%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Barrington Research
Michael Petusky
53% 1-year accuracy
25 / 47 met price target
1%downside
$92
Outperform
Maintained
20 Sept 2024
JMP Securities
Daniel Stauder
0% 1-year accuracy
0 / 2 met price target
8%upside
$100
Market Outperform
Maintained
20 Aug 2024
Barrington Research
Michael Petusky
53% 1-year accuracy
25 / 47 met price target
12%downside
$82
Outperform
Maintained
2 Aug 2024

Financial journalist opinion

Charts implemented using Lightweight Charts™